Company: TVRD
Filing Date: 2025-02-14
Form Type: 424B3
Source: 0001104659-25-014310
Chunk: 869

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-02-14
Form: 424B3
Chunk 869
---
 ​                       | ​ | ​ | ​ | ​ |
| Options exercisable, December 31, 2023                                         | ​ | ​ | ​               | ​ |  403,337 | ​ | ​ | ​ | ​                             | $ | 176.28 | ​ | ​ | ​ | ​                       | $ | — | ​ | ​ |
| Weighted average remaining contractual life as of December 31, 2023 (in years) | ​ | ​ | ​               | ​ |     5.46 | ​ | ​ | ​ | ​                             | ​ |      ​ | ​ | ​ | ​ | ​                       | ​ | ​ | ​ | ​ |
| Options vested and expected to vest as of December 31, 2023                    | ​ | ​ | ​               | ​ |  658,138 | ​ | ​ | ​ | ​                             | $ | 155.88 | ​ | ​ | ​ | ​                       | $ | — | ​ | ​ |
| Weighted average remaining contractual life as of December 31, 2023 (in years) | ​ | ​ | ​               | ​ |     6.71 | ​ | ​ | ​ | ​                             | ​ |      ​ | ​ | ​ | ​ | ​                       | ​ | ​ | ​ | ​ |

The total fair value of options vested during the years ended December 31, 2023, 2022 and 2021 was $12,810, $14,156, and $12,844, respectively. The intrinsic value of options exercised during the years ended December 31, 2023, 2022 and 2021 was $476, $118, and $965, respectively. During the years ended December 31, 2023, 2022 and 2021, the Company granted 167,056, 158,327 and 118,553 stock options, respectively, to employees and non-employee members of the Board of Directors. There were no options granted to nonemployee consultants during the years ended December 31, 2023, 2022 and 2021. The fair values of the stock options granted to those groups were estimated using the Black-Scholes option valuation model with the following ranges of assumptions (see Note 2, Summary of Significant Accounting Policies — Stock-Based Compensation ):

F-78

TABLE OF CONTENTS

CARA THERAPEUTICS, INC. NOTES TO CONSOLIDATED FINANCIAL STATE